Anxiety Disorders Completed Phase 3 Trials for Naluzotan (DB05562)

Also known as: Anxiety Disorder / Anxiety NOS

IndicationStatusPhase
DBCOND0027904 (Anxiety Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00248183A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)Treatment